- Home
- EBS vs EYPT Comparison
EBS vs EYPT Comparison
Compare EBS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- EYPT
- Stock Information
- Founded
- EBS 1998
- EYPT 1987
- Country
- EBS United States
- EYPT United States
- Employees
- EBS N/A
- EYPT N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- EBS Health Care
- EYPT Industrials
- Exchange
- EBS Nasdaq
- EYPT Nasdaq
- Market Cap
- EBS 393.9M
- EYPT 427.9M
- IPO Year
- EBS 2006
- EYPT 2005
- Fundamental
- Price
- EBS $5.04
- EYPT $6.84
- Analyst Decision
- EBS Strong Buy
- EYPT Strong Buy
- Analyst Count
- EBS 3
- EYPT 8
- Target Price
- EBS $14.33
- EYPT $25.71
- AVG Volume (30 Days)
- EBS 1.2M
- EYPT 841.5K
- Earning Date
- EBS 05-07-2025
- EYPT 05-07-2025
- Dividend Yield
- EBS N/A
- EYPT N/A
- EPS Growth
- EBS N/A
- EYPT N/A
- EPS
- EBS N/A
- EYPT N/A
- Revenue
- EBS $1,043,600,000.00
- EYPT $43,273,000.00
- Revenue This Year
- EBS N/A
- EYPT N/A
- Revenue Next Year
- EBS $19.88
- EYPT N/A
- P/E Ratio
- EBS N/A
- EYPT N/A
- Revenue Growth
- EBS N/A
- EYPT N/A
- 52 Week Low
- EBS $1.82
- EYPT $3.91
- 52 Week High
- EBS $15.10
- EYPT $21.26
- Technical
- Relative Strength Index (RSI)
- EBS 48.72
- EYPT 64.76
- Support Level
- EBS $4.13
- EYPT $5.37
- Resistance Level
- EBS $4.69
- EYPT $5.86
- Average True Range (ATR)
- EBS 0.35
- EYPT 0.56
- MACD
- EBS 0.15
- EYPT 0.24
- Stochastic Oscillator
- EBS 94.91
- EYPT 98.83
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.